Results 141 to 150 of about 252,333 (374)

Amyloid‐Related Imaging Abnormality (ARIA) Beyond the APOE‐ε4 Allele

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Mechanism of action of monoclonal antibodies targeting Aβ in the treatment of AD. (A) Targets of various mAbs. (B) Mechanism of monoclonal antibody‐mediated clearance of Aβ. mAbs facilitate the clearance of Aβ by enhancing microglial‐mediated phagocytosis through the upregulation of TREM2 expression.
Valentinus Besin   +5 more
wiley   +1 more source

Deferasirox Derivatives as Inhibitors of Kallikrein‐Related Peptidases Associated to Neurodegenerative Diseases

open access: yesChemMedChem, EarlyView.
Dysregulated proteolysis mediated by kallikrein‐related peptidases (KLKs) and iron overload are involved in the progression of neurodegenerative diseases. Deferasirox, an clinically‐approved iron chelator, and its newly synthesized derivatives have been identified as inhibitors of major central nervous system KLKs with low cytotoxicity and effective ...
Rilès Boumali   +11 more
wiley   +1 more source

Quantitative diagnosis of amyloid without Congo red staining using polarized light microscopy [PDF]

open access: yesarXiv
Amyloidosis is a protein misfolding disease caused by the deposition of large, insoluble aggregates (amyloid fibrils) of protein in a tissue, which has been associated with various conditions, such as lymphoid disorders, Alzheimer's disease, diabetes mellitus type 2, chronic inflammatory processes, and cancers. Amyloid fibrils are commonly diagnosed by
arxiv  

Deposition of amyloid fibrils promotes cell-surface accumulation of amyloid β precursor protein

open access: yesNeurobiology of Disease, 2004
Amyloid β protein (Aβ) deposition and neuronal degeneration are characteristic pathological features of Alzheimer's disease (AD). In vitro, Aβ fibrils (fAβ) induce neuronal degeneration reminiscent to AD, but the mechanism of neurotoxicity is unknown ...
Lorena Heredia   +5 more
doaj  

Increased gene expression of Alzheimer disease beta-amyloid precursor protein in senescent cultured fibroblasts. [PDF]

open access: green, 1991
Mark J. Adler   +4 more
openalex   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang   +7 more
wiley   +1 more source

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi   +6 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy in aortic stenosis patients scheduled for transcatheter aortic valve implantation

open access: yesESC Heart Failure, EarlyView.
Abbreviations: TAVI, transcatheter aortic valve implantation; ATTR‐CM, transthyretin cardiac amyloidosis. We aimed to diagnose occult ATTR‐CM in patients with severe aortic stenosis undergoing TAVI using bone scintigraphy. We verified a diagnosis of ATTR‐CM in 8 of 171 (4.7 %) consecutive aortic stenosis patients who underwent TAVI.
Margrethe Flesvig Holt   +15 more
wiley   +1 more source

Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics

open access: yesProteins: Structure, Function, and Bioinformatics, EarlyView., 2023
Abstract Before the controversial approval of humanized monoclonal antibody lecanemab, which binds to the soluble amyloid‐β protofibrils, all the treatments available earlier, for Alzheimer's disease (AD) were symptomatic. The researchers are still struggling to find a breakthrough in AD therapeutic medicine, which is partially attributable to lack in ...
Sharif Arar   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy